Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Study reveals new way to ‘rewire’ immune cells to slow tumor growth
Inside a tumor, immune cells and cancer cells battle for survival. The advantage may go to the cells that metabolize the most glucose, say Yale researchers who have identified a new way to boost immune response by metabolically “rewiring” immune cells.
Targeting a Deadly Type of Uterine Cancer
Endometrial cancer, which originates in the lining of the uterus and is the most common type of gynecological cancer, often has a good prognosis. Patients with the more frequently diagnosed type I are often cured. Type II, however, is responsible for most of the recurrences and deaths that occur in endometrial cancer. Uterine Serous Carcinoma (USC), the most aggressive kind of type II endometrial cancer, accounts for just 10 percent of endometrial tumors and is particularly deadly: in its earliest stages the survival rate can be as low as 50 percent, and for those with more advanced disease, there is no cure.
$7.5 Million Grant to Yale Researchers for Role of Viruses in Cancer
The National Cancer Institute recently awarded a five-year, $7.5 million program project grant to investigators at the Yale School of Medicine to continue studies on the role of viruses and mutant cellular proteins in tumorigenic transformation of cells.
Jawless Lamprey Takes a Bite out of Oncogene Evolution
By carefully tracing the evolution of a select number of cancer-causing genes in a variety of species, the researchers evaluated which animals are — and are not — effective in gauging how an analogue of those genes in humans can lead to cancer. What they found is surprising: jawless fish such as lampreys share significant similarities in these certain genes compared to humans, while fruit flies do not.
New Immunotherapy Treatment for Lung Cancer
More than 200,000 people a year in the United States are diagnosed with non-small cell lung cancers, which make up about 80 percent of all lung cancers. Now, the results of a phase three clinical trial show the immunotherapy drug atezolizumab, also known as Tecentriq, improves survival.Source: ABC News 12
Breast Cancer: Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies
In HER2-positive early stage (stage I-II) breast cancer, several different preoperative (also called neoadjuvant) chemotherapy options exist, each of these is associated with a different rate of complete eradication of cancer from the breast and lymph nodes (called pathologic complete response or pCR). Patients who experience pCR have excellent long term survival.Source: MedicalResearch.com
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Yale Doc Says Lowering Recommended Age For Colon Screening is Critical Following Rise in Colorectal Cancer in Younger Patients
The United States Preventative Services taskforce has released a recommendation that colon cancer screenings start at age 45 instead of 50. It’s because more young people are being diagnosed with colon cancer. Dr. Pamela Kunz says the new recommendation is due to the staggering hike in younger cases of colon cancer.Source: WTNH News 8
The Yale Larynx Lab chosen as cover of Oncotarget, Vol 11, Issue 35
The cover for issue 35 of Oncotarget features Figure 4, "The in vivo pre- or post- topical application of BAY 11-7082 prevents the acidic bile-induced deregulation of cancer-related miRNA markers in 10-day exposed murine HM," by Vageli, et. al.
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.